Key statistics
On Tuesday, Altamira Therapeutics Ltd (CYTO:NAQ) closed at 0.635, 5.83% above its 52-week low of 0.600, set on Oct 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.62 |
---|---|
High | 0.643 |
Low | 0.619 |
Bid | 0.61 |
Offer | 0.635 |
Previous close | 0.62 |
Average volume | 57.18k |
---|---|
Shares outstanding | 3.78m |
Free float | 3.76m |
P/E (TTM) | 0.9355 |
Market cap | 2.40m USD |
EPS (TTM) | 0.6788 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 20:58 BST.
More ▼
Announcements
- Altamira Therapeutics Provides Update on Nasdaq Listing
- Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
- Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
- Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
- Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
- Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
- Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
- Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11
- Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
- Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
More ▼